Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

CervoMed Inc.

NASDAQ: CRVO · Life Sciences · 8 alerts · CIK 1053691

Share price
$1.67Close, Nov 16
Market cap
$25.3M
Shares outstanding
15.13MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CervoMed Inc. filings on SEC EDGAR ↗

4:29 PM ET 8-K
Clinical Trial Data

CervoMed Clinical Trial Data

CervoMed presented 24-week interim biomarker data from its Phase 2a trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed an exposure-dependent reduction in neurofilament light chain (NfL), a key biomarker of neuronal damage, in patients with higher plasma drug levels. Full 24-week biomarker and clinical data from the study are expected in the first quarter of 2027.

Term
24 weeks
4:20 PM ET 8-K
Clinical Trial Data

CervoMed Clinical Trial Data

CervoMed announced the publication of peer-reviewed results from its Phase 2b RewinD-LB clinical trial of neflamapimod in dementia with Lewy bodies (DLB). While the trial did not meet its primary endpoint in the full population, data showed a statistically significant increase in right basal forebrain volume and greater clinical benefit in patients without Alzheimer’s disease co-pathology.

8:36 AM ET 8-K
Clinical Trial Data

CervoMed Clinical Trial Data

CervoMed announced positive initial 12-week biomarker data from its Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed a mean reduction in plasma neurofilament light chain (NfL) levels, a key marker of neurodegeneration, which contrasts with the increases typically seen in the natural history of the disease.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.